Related Experiment Video

Updated: Jul 15, 2026

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton

Frederick S Kaplan1, David L Glaser, Robert J Pignolo

  • 1University of Pennsylvania School of Medicine, Department of Orthopaedic Surgery, Hospital of the University of Pennsylvania, Silverstein Two, 34th & Spruce Street, Philadelphia, PA 19104, USA. frederick.kaplan@uphs.upenn.edu

Expert Opinion on Biological Therapy
|May 5, 2007
PubMed

Insights

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder causing a second skeleton. A specific gene mutation discovery offers a potential therapeutic target for FOP and other heterotopic ossification conditions.

Area of Science:

  • Genetics
  • Molecular Biology
  • Biochemistry

Background:

  • Fibrodysplasia ossificans progressiva (FOP) is a severe genetic disorder characterized by progressive heterotopic ossification, leading to debilitating joint immobilization.
  • Currently, no effective treatments or preventive measures exist for FOP, highlighting an urgent need for therapeutic interventions.

Purpose of the Study:

  • To identify the genetic basis of Fibrodysplasia ossificans progressiva (FOP).
  • To explore potential therapeutic targets within the identified signaling pathway for FOP treatment.

Main Methods:

  • Genetic analysis of sporadic and familial cases of classic FOP.
  • Identification of mutations in the activin receptor IA/activin-like kinase-2 gene.

Main Results:

  • A recurrent mutation in the glycine-serine activation domain of activin receptor IA/activin-like kinase-2 was identified in all classic FOP cases.
  • This mutation represents one of the most specific disease-causing mutations known in the human genome.

Conclusions:

  • The discovery of the FOP gene is a significant milestone, providing a druggable target within the TGF-beta/bone morphogenetic protein signaling pathway.
  • Therapeutic strategies focusing on small molecule inhibitors for activin-like kinase-2 are promising for treating FOP and potentially other heterotopic ossification disorders.

More Related Videos

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

Related Concept Videos

Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Formation by Endochondral Ossification01:24

Bone Formation by Endochondral Ossification

Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Fractures: Bone Repair01:27

Fractures: Bone Repair

Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...